Company Overview
AquaBounty Technologies, Inc. operates as a land-based aquaculture company based in the United States, specializing in the development and commercialization of genetically enhanced Atlantic salmon intended for the aquaculture industry. The corporation functions within the Consumer Defensive sector, specifically under the Farm Products industry, which generally implies businesses involved in the production or processing of essential goods that may face less cyclical volatility than discretionary sectors, though the specific dynamics of aquaculture can vary. As of the latest reporting period, the company maintains a market capitalization of $3.43 million and reports a trailing twelve-month revenue of $-47,812, while employing a workforce of just four individuals. The combination of a sub-$4 million market cap and negative revenue alongside a minimal headcount of four employees indicates that the company is in an extremely early-stage or distressed position, likely reflecting a phase of significant operational contraction or a failure to generate commercial sales at a scale that supports positive financial performance.
Financial Health
The company reported a trailing twelve-month revenue of $-47,812 and a net income of $-82,136,968, revealing a cost structure where losses far exceed any nominal revenue generation, suggesting the business is currently burning cash without a viable path to immediate profitability. Despite the negative net income, the company lists free cash flow at $23.69 million, a figure that creates a complex and contradictory picture regarding the company's financial flexibility and operational reality, as positive free cash flow is typically impossible without positive operating cash inflows. The margin profile presents extreme anomalies, with a gross margin of 0.0% and a profit margin of 0.0%, indicating that the company has not generated a profit on its sales or costs, while the operating margin is reported as an anomalous 14293.5%, which likely results from accounting adjustments or non-operating items rather than core operational efficiency. On the balance sheet, the company holds $951,434 in cash against $7.94 million in debt, resulting in a debt-to-equity ratio of 64.88, which signifies a highly leveraged and precarious financial position where liabilities significantly outweigh equity. Liquidity is severely constrained, evidenced by a current ratio of 0.12, which indicates that the company's current assets are insufficient to cover its current liabilities without accessing external financing or selling long-term assets. Return on Equity stands at -146.3% and Return on Assets is -6.0%, metrics that reveal management has been ineffective at generating positive returns on the capital invested in the business, with equity value being eroded at a rate exceeding 100% annually.
Valuation Assessment
Valuation metrics for AquaBounty Technologies, Inc. present significant distortions due to the company's loss-making status, with a trailing P/E ratio listed as N/A and a forward P/E of -0.39, implying that the market prices the stock based on negative earnings expectations rather than traditional profit-based valuation models. The price-to-book ratio is recorded at 0.28, suggesting that the market values the company at less than 30% of its book value, which often indicates a deep undervaluation of assets or, conversely, a high risk of bankruptcy that has depressed the stock price below tangible book value. Alternative valuation metrics such as the price-to-sales ratio of -71.78 and an EV/EBITDA of -1.70 further highlight the company's financial distress, as negative multiples reflect the inability to generate positive earnings or sales relative to the market price. The stock has exhibited significant volatility, trading between a 52-week high of $2.95 and a 52-week low of $0.54, meaning the current price sits well below the recent high and reflects the extreme risk premium associated with such a speculative asset. The company carries a beta of 1.31, indicating that its share price is expected to be 31% more volatile than the broader market, a characteristic typical of small-cap biotechnology or agritech firms facing high uncertainty and regulatory hurdles.
Growth & Income
Growth rates for both revenue and earnings are listed as N/A, preventing a direct comparison of whether earnings are growing faster or slower than revenue, but the negative revenue figure suggests the company is not currently expanding its top line in a traditional commercial sense. As a non-dividend payer, the company offers a dividend yield of N/A and maintains a payout ratio of 0.0%, meaning the firm does not distribute cash to shareholders and theoretically reinvests any available capital or retains earnings to fund operations, though the massive net loss suggests funds are being consumed rather than invested for growth. The overall growth and income profile is characterized by a complete absence of positive earnings growth, zero dividend income, and a reliance on a small cash reserve to service debt and cover operating expenses. This profile indicates that the investment thesis relies entirely on future turnaround potential rather than current financial performance, income generation, or historical growth momentum.